Earnings call transcript: Devyser Diagnostics Q2 2025 revenue beats forecast

Devyser Diagnostics AB reported robust Q2 2025 financial results, with revenue reaching SEK 67.4 million, a 27% year-over-year increase that significantly surpassed expectations, leading to an 8.03% surge in its stock price. The company achieved a record EBIT of SEK 5.5 million and an 84.2% gross margin, primarily driven by a 200% quarter-over-quarter growth in the US market and successful cost control measures from its recent reorganization. Devyser is advancing new product launches and the FDA approval process for its transplantation diagnostics, maintaining a positive outlook with targets for 30% annual organic growth and a 20% EBIT margin by 2026, signaling strong operational momentum and a clear path to sustained profitability.

Analysis

Devyser Diagnostics AB (DVYSR) delivered a robust financial performance in Q2 2025, signaling strong operational momentum and progress towards its long-term profitability goals. The company reported record revenue of SEK 67.4 million, a 27% year-over-year increase that surpassed the SEK 61.93 million forecast, triggering an 8.03% rise in its stock price. This top-line strength was underpinned by an exceptional 200% quarter-over-quarter growth in the US market and a solid contribution from distributor sales, particularly via the Thermo Fisher partnership. Critically, the company achieved a record EBIT of SEK 5.5 million and a high gross margin of 84.2%, demonstrating significant operational leverage from its recently completed reorganization and improved cost controls. Management's guidance reaffirms confidence, targeting 30% annual organic growth and a 20% EBIT margin by 2026. Key future catalysts include the commercialization of its RHD test through a major US service provider in Q3 and regulatory progress, where feedback on its MolDX submission was viewed as an 'achievable deliverable' and an FDA pre-submission meeting confirmed its transplantation product strategy is 'on the right track'. While softer sales in Asia Pacific and phasing in the Italian market represent potential headwinds, the overall results reflect a successful strategic execution and a strengthening commercial pipeline.

Key Decisions for Investors

• Investors should recognize the company's demonstrated ability to combine strong top-line growth, evidenced by the 27% YoY revenue increase, with operational discipline leading to record EBIT and a clear path toward its 2026 profitability targets.
• It is critical to monitor progress on key near-term catalysts, including the resubmission of the MolDX application for reimbursement and further updates on the FDA approval timeline for transplantation products, as positive outcomes could significantly de-risk the US commercialization strategy.
• The performance of the Thermo Fisher partnership and the successful execution of the upcoming partnership to commercialize the RHD test in the US will be key indicators of the company's ability to scale market penetration and validate its channel strategy.
• While the stock is trading near its 52-week high, the positive revenue beat and strong guidance suggest the market's optimistic sentiment is well-founded, but investors should remain watchful of execution in the Italian market and any developments in the softer Asia Pacific region.